Filing Details
- Accession Number:
- 0001415889-24-020106
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-25 16:32:39
- Reporting Period:
- 2024-07-23
- Accepted Time:
- 2024-07-25 16:32:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1730430 | Kiniksa Pharmaceuticals International Plc | KNSA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1835458 | Mark Ragosa | 23 Old Bond Street, Third Floor London X0 W1S 4PZ | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Ordinary Share | Acquisiton | 2024-07-23 | 24,248 | $11.10 | 43,501 | No | 4 | M | Direct | |
Class A Ordinary Share | Disposition | 2024-07-23 | 24,248 | $24.79 | 19,253 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Ordinary Share | Share Option | Disposition | 2024-07-23 | 24,248 | $0.00 | 24,248 | $11.10 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
40,412 | 2032-04-06 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between $24.72 and $25.095. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.